WuXi XDC Cayman (STU:L74) Total Equity: €1,300.5 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:L74 WuXi XDC Cayman Inc STU:L74
50 GF Score
Price €7.50
! 3 Warning Signs
View Full Analysis

What is WuXi XDC Cayman Total Equity?

WuXi XDC Cayman STU:L74 -5.06% 50 Total Equity is €1,300.5 Mil as of Dec. 2025. GuruFocus rates STU:L74 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review.

WuXi XDC Cayman's total equity for the quarter that ended in Dec. 2025 was €1,300.5 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

WuXi XDC Cayman Total Equity Historical Data

* Premium members only.

The historical data trend for WuXi XDC Cayman's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi XDC Cayman Total Equity Chart

WuXi XDC Cayman Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 2.90 200.50 700.49 870.89 1,300.48

WuXi XDC Cayman Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 767.19 870.89 898.64 1,300.48 1,482.69
STU:L74
50GF Score
WuXi XDC Cayman Inc STU:L74
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WuXi XDC Cayman Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

WuXi XDC Cayman's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1750.291-449.808
=1,300.5

WuXi XDC Cayman's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1750.291-449.808
=1,300.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €1,300.5 Mil mean?
WuXi XDC Cayman (STU:L74) has a Total Equity of €1,300.5 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for WuXi XDC Cayman and its competitors.
Is WuXi XDC Cayman's Total Equity too high?
WuXi XDC Cayman's current Total Equity is €1,300.5 Mil. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's Total Equity compare to TMO and DHR?
WuXi XDC Cayman's Total Equity of €1,300.5 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Diagnostics & Research company?
A good Total Equity depends on the Medical Diagnostics & Research industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for WuXi XDC Cayman and its competitors. WuXi XDC Cayman's current Total Equity is €1,300.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (STU:L74) has a current Total Equity of €1,300.5 Mil. The current Total Equity is €1,300.5 Mil. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For WuXi XDC Cayman (STU:L74), the current Total Equity is €1,300.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

WuXi XDC Cayman Business Description

Other Exchanges 02268:Hong KongL74:Germany
Address No. 11 Xinhui Ring Road, Xinwu, Jiangsu Province, Wuxi, CHN
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score

Get the complete analysis for STU:L74

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.50
Price